Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMERTQ4)

• Drug Name: 4-Amino-3-chloro-benzenesulfonamide Drug Info
• Synonyms: 4-amino-3-chlorobenzenesulfonamide

Indication

Disease Entry	ICD 11	Status	REF
Discovery agent	N.A.	Investigative	[1]

• Cross-matching ID:
  PubChem CID: 1502014
  CAS Number: CAS 53297-68-0
  TTD Drug ID: DMERTQ4

Molecule-Related Drug Atlas

Drug(s) Targeting Carbonic anhydrase VI (CA-VI)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Salicyclic acid	DM2F8XZ	Acne vulgaris	ED80	Approved	[7]
Sulfamylon	DMIO1K0	Bacterial infection	1A00-1C4Z	Approved	[1]
Curcumin	DMQPH29	Solid tumour/cancer	2A00-2F9Z	Phase 3	[8]
PARABEN	DMEW5Z8	N. A.	N. A.	Phase 3	[9]
Coumate	DMVKW0N	Breast cancer	2C60-2C65	Phase 2	[10]
SAR566658	DM6Q295	Solid tumour/cancer	2A00-2F9Z	Phase 2	[11]
FERULIC ACID	DMJC7NF	Discovery agent	N.A.	Patented	[9]
SPERMINE	DMD4BFY	N. A.	N. A.	Terminated	[12]
ELLAGIC ACID	DMX8BS5	Discovery agent	N.A.	Investigative	[9]
COUMARIN	DM0N8ZM	Discovery agent	N.A.	Investigative	[13]

Drug(s) Targeting Carbonic anhydrase I (CA-I)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Salicyclic acid	DM2F8XZ	Acne vulgaris	ED80	Approved	[7]
Ethoxzolamide	DMVO4ED	Glaucoma/ocular hypertension	9C61	Approved	[14]
Dichlorphenamide	DMH7IDQ	Chronic glaucoma	9C61.0Z	Approved	[14]
Methazolamide	DM7J2TA	Glaucoma/ocular hypertension	9C61	Approved	[15]
Acetazolamide	DM1AF5U	Absence epilepsy		Approved	[14]
Curcumin	DMQPH29	Solid tumour/cancer	2A00-2F9Z	Phase 3	[8]
PARABEN	DMEW5Z8	N. A.	N. A.	Phase 3	[9]
CG-100649	DMIKMA9	Arthritis	FA20	Phase 3	[16]
PHENOL	DM1QSM3	N. A.	N. A.	Phase 2/3	[8]
Coumate	DMVKW0N	Breast cancer	2C60-2C65	Phase 2	[10]

Drug(s) Targeting Carbonic anhydrase XII (CA-XII)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Salicyclic acid	DM2F8XZ	Acne vulgaris	ED80	Approved	[7]
Sulfamylon	DMIO1K0	Bacterial infection	1A00-1C4Z	Approved	[17]
Curcumin	DMQPH29	Solid tumour/cancer	2A00-2F9Z	Phase 3	[8]
PARABEN	DMEW5Z8	N. A.	N. A.	Phase 3	[9]
PHENOL	DM1QSM3	N. A.	N. A.	Phase 2/3	[8]
Coumate	DMVKW0N	Breast cancer	2C60-2C65	Phase 2	[10]
FERULIC ACID	DMJC7NF	Discovery agent	N.A.	Patented	[9]
ELLAGIC ACID	DMX8BS5	Discovery agent	N.A.	Investigative	[9]
COUMARIN	DM0N8ZM	Discovery agent	N.A.	Investigative	[13]
CATECHIN	DMY38SB	Discovery agent	N.A.	Investigative	[8]

Drug(s) Targeting Carbonic anhydrase II (CA-II)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Salicyclic acid	DM2F8XZ	Acne vulgaris	ED80	Approved	[7]
Sulfamylon	DMIO1K0	Bacterial infection	1A00-1C4Z	Approved	[17]
Dorzolamide	DMA17D0	Ocular hypertension	9C61.01	Approved	[2]
Chlorothiazide	DMLHESP	Chronic heart failure	BD1Z	Approved	[18]
Ethoxzolamide	DMVO4ED	Glaucoma/ocular hypertension	9C61	Approved	[19]
Dichlorphenamide	DMH7IDQ	Chronic glaucoma	9C61.0Z	Approved	[19]
Cyclothiazide	DMJ4AWC	Congestive heart failure	BD10	Approved	[20]
Ethinamate	DMK57GB	Insomnia	7A00-7A0Z	Approved	[21]
Benzthiazide	DMQWZ0H	High blood pressure	BA00	Approved	[22]
Curcumin	DMQPH29	Solid tumour/cancer	2A00-2F9Z	Phase 3	[8]

Drug(s) Targeting Carbonic anhydrase XIV (CA-XIV)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Sulfamylon	DMIO1K0	Bacterial infection	1A00-1C4Z	Approved	[6]
TRIENTINE	DMD2WPG	Inborn error of metabolism	5C50-5C59	Approved	[12]
Curcumin	DMQPH29	Solid tumour/cancer	2A00-2F9Z	Phase 3	[8]
PARABEN	DMEW5Z8	N. A.	N. A.	Phase 3	[9]
PHENOL	DM1QSM3	N. A.	N. A.	Phase 2/3	[8]
Coumate	DMVKW0N	Breast cancer	2C60-2C65	Phase 2	[10]
FERULIC ACID	DMJC7NF	Discovery agent	N.A.	Patented	[9]
SPERMINE	DMD4BFY	N. A.	N. A.	Terminated	[12]
ELLAGIC ACID	DMX8BS5	Discovery agent	N.A.	Investigative	[9]
COUMARIN	DM0N8ZM	Discovery agent	N.A.	Investigative	[13]

Drug(s) Targeting Carbonic anhydrase (CA)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Salicyclic acid	DM2F8XZ	Acne vulgaris	ED80	Approved	[23]
Sulfamylon	DMIO1K0	Bacterial infection	1A00-1C4Z	Approved	[1]
Quinethazone	DMWCOSR	Hypertension	BA00-BA04	Approved	[24]
Curcumin	DMQPH29	Solid tumour/cancer	2A00-2F9Z	Phase 3	[8]
PARABEN	DMEW5Z8	N. A.	N. A.	Phase 3	[9]
PHENOL	DM1QSM3	N. A.	N. A.	Phase 2/3	[8]
Coumate	DMVKW0N	Breast cancer	2C60-2C65	Phase 2	[10]
SULFAMIDE	DMMAS3K	N. A.	N. A.	Phase 1	[25]
FERULIC ACID	DMJC7NF	Discovery agent	N.A.	Patented	[9]
PMID30074415-Compound-21	DM3NPOU	N. A.	N. A.	Patented	[26]

Drug(s) Targeting Carbonic anhydrase IV (CA-IV)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Salicyclic acid	DM2F8XZ	Acne vulgaris	ED80	Approved	[7]
Sulfamylon	DMIO1K0	Bacterial infection	1A00-1C4Z	Approved	[4]
Brinzolamide	DMBAPFG	Ocular hypertension	9C61.01	Approved	[14]
Curcumin	DMQPH29	Solid tumour/cancer	2A00-2F9Z	Phase 3	[8]
PARABEN	DMEW5Z8	N. A.	N. A.	Phase 3	[9]
PHENOL	DM1QSM3	N. A.	N. A.	Phase 2/3	[8]
Coumate	DMVKW0N	Breast cancer	2C60-2C65	Phase 2	[10]
Sodium pyruvate	DMST6A3	Asthma	CA23	Phase 1/2	[27]
SULFAMIDE	DMMAS3K	N. A.	N. A.	Phase 1	[25]
FERULIC ACID	DMJC7NF	Discovery agent	N.A.	Patented	[9]

Drug(s) Targeting Carbonic anhydrase IX (CA-IX)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Curcumin	DMQPH29	Solid tumour/cancer	2A00-2F9Z	Phase 3	[8]
PARABEN	DMEW5Z8	N. A.	N. A.	Phase 3	[9]
PHENOL	DM1QSM3	N. A.	N. A.	Phase 2/3	[8]
Coumate	DMVKW0N	Breast cancer	2C60-2C65	Phase 2	[10]
INDISULAM	DM9SX6Y	Lymphoma	2A80-2A86	Phase 2	[28]
Girentuximab I-124	DMG3O2Z	Renal cell carcinoma	2C90	Phase 2	[29]
SULFAMIDE	DMMAS3K	N. A.	N. A.	Phase 1	[30]
BAY 79-4620	DM14XQN	Solid tumour/cancer	2A00-2F9Z	Phase 1	[31]
90Y-cG250	DMJR6TC	Solid tumour/cancer	2A00-2F9Z	Phase 1	[32]
FERULIC ACID	DMJC7NF	Discovery agent	N.A.	Patented	[9]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Carbonic anhydrase (CA)	TTUNARX	NOUNIPROTAC	Inhibitor	[1]
Carbonic anhydrase I (CA-I)	TTHQPL7	CAH1_HUMAN	Inhibitor	[2]
Carbonic anhydrase II (CA-II)	TTANPDJ	CAH2_HUMAN	Inhibitor	[3]
Carbonic anhydrase IV (CA-IV)	TTZHA0O	CAH4_HUMAN	Inhibitor	[4]
Carbonic anhydrase IX (CA-IX)	TT2LVK8	CAH9_HUMAN	Inhibitor	[1]
Carbonic anhydrase VI (CA-VI)	TTCFSPE	CAH6_HUMAN	Inhibitor	[1]
Carbonic anhydrase XII (CA-XII)	TTSYM0R	CAH12_HUMAN	Inhibitor	[5]
Carbonic anhydrase XIV (CA-XIV)	TTEYTKG	CAH14_HUMAN	Inhibitor	[6]

References

• [1] Cloning, expression, post-translational modifications and inhibition studies on the latest mammalian carbonic anhydrase isoform, CA XV. J Med Chem. 2009 Feb 12;52(3):646-54.
• [2] Carbonic anhydrase inhibitors. Inhibition studies of a coral secretory isoform by sulfonamides. Bioorg Med Chem. 2009 Jul 15;17(14):5054-8.
• [3] Carbonic anhydrase inhibitors. Characterization and inhibition studies of the most active beta-carbonic anhydrase from Mycobacterium tuberculosis, ... Bioorg Med Chem Lett. 2009 Dec 1;19(23):6649-54.
• [4] Carbonic anhydrase inhibitors. Inhibition of the membrane-bound human and bovine isozymes IV with sulfonamides. Bioorg Med Chem Lett. 2005 Feb 15;15(4):1149-54.
• [5] Carbonic anhydrase inhibitors. Inhibition of the transmembrane isozyme XII with sulfonamides-a new target for the design of antitumor and antiglauc... Bioorg Med Chem Lett. 2005 Feb 15;15(4):963-9.
• [6] Carbonic anhydrase inhibitors: inhibition of the transmembrane isozyme XIV with sulfonamides. Bioorg Med Chem Lett. 2005 Sep 1;15(17):3828-33.
• [7] Carbonic anhydrase inhibitors: inhibition of mammalian isoforms I-XIV with a series of substituted phenols including paracetamol and salicylic acid. Bioorg Med Chem. 2008 Aug 1;16(15):7424-8.
• [8] Carbonic anhydrase inhibitors. Antioxidant polyphenols effectively inhibit mammalian isoforms I-XV. Bioorg Med Chem Lett. 2010 Sep 1;20(17):5050-3.
• [9] Carbonic anhydrase inhibitors. Inhibition of mammalian isoforms I-XIV with a series of natural product polyphenols and phenolic acids. Bioorg Med Chem. 2010 Mar 15;18(6):2159-2164.
• [10] Carbonic anhydrase inhibitors. Interaction of the antitumor sulfamate EMD 486019 with twelve mammalian carbonic anhydrase isoforms: Kinetic and X-r... Bioorg Med Chem Lett. 2008 Aug 1;18(15):4282-6.
• [11] An Antibody-Drug Conjugate Targeting MUC1-Associated Carbohydrate CA6 Shows Promising Antitumor Activities. Mol Cancer Ther. 2020 Aug;19(8):1660-1669.
• [12] Polyamines inhibit carbonic anhydrases by anchoring to the zinc-coordinated water molecule. J Med Chem. 2010 Aug 12;53(15):5511-22.
• [13] Deciphering the mechanism of carbonic anhydrase inhibition with coumarins and thiocoumarins. J Med Chem. 2010 Jan 14;53(1):335-44.
• [14] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
• [15] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2597).
• [16] Understanding the Dual Inhibition of COX-2 and Carbonic Anhydrase-II by Celecoxib and CG100649 Using Density Functional Theory Calculations and other Molecular Modelling Approaches. Protein Pept Lett. 2015;22(10):903-12.
• [17] Sulfonamide linked neoglycoconjugates--a new class of inhibitors for cancer-associated carbonic anhydrases. J Med Chem. 2010 Apr 8;53(7):2913-26.
• [18] Localization of diuretic effects along the loop of Henle: an in vivo microperfusion study in rats. Clin Sci (Lond). 2000 Apr;98(4):481-8.
• [19] The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42.
• [20] Selective effect of thiazides on the human osteoblast-like cell line MG-63. Kidney Int. 1996 Nov;50(5):1476-82.
• [21] Inhibition of carbonic anhydrases I and II by N-unsubstituted carbamate esters. J Biol Chem. 1992 Dec 15;267(35):25044-50.
• [22] Nature of the inhibition of carbonic anhydrase by acetazolamide and benzthiazide. J Pharmacol Exp Ther. 1961 Mar;131:271-4.
• [23] Carbonic anhydrase inhibitors: Inhibition of the new membrane-associated isoform XV with phenols. Bioorg Med Chem Lett. 2008 Jun 15;18(12):3593-6.
• [24] Carbonic anhydrase inhibitors. Interaction of indapamide and related diuretics with 12 mammalian isozymes and X-ray crystallographic studies for th... Bioorg Med Chem Lett. 2008 Apr 15;18(8):2567-73.
• [25] Carbonic anhydrase inhibitors: crystallographic and solution binding studies for the interaction of a boron-containing aromatic sulfamide with mamm... Bioorg Med Chem Lett. 2010 Jun 15;20(12):3601-5.
• [26] Carbonic anhydrase inhibitors as antitumor/antimetastatic agents: a patent review (2008-2018).Expert Opin Ther Pat. 2018 Oct;28(10):729-740.
• [27] Carbonic anhydrase inhibitors. Interaction of isozymes I, II, IV, V, and IX with carboxylates. Bioorg Med Chem Lett. 2005 Feb 1;15(3):573-8.
• [28] Carbonic anhydrase inhibitors: E7070, a sulfonamide anticancer agent, potently inhibits cytosolic isozymes I and II, and transmembrane, tumor-assoc... Bioorg Med Chem Lett. 2004 Jan 5;14(1):217-23.
• [29] Potential role of (124)I-girentuximab in the presurgical diagnosis of clear-cell renal cell cancer. Biologics. 2012;6:395-407.
• [30] Carbonic anhydrase inhibitors. Inhibition of isozymes I, II, IV, V, and IX with anions isosteric and isoelectronic with sulfate, nitrate, and carbo... Bioorg Med Chem Lett. 2005 Feb 1;15(3):567-71.
• [31] Therapeutic mechanism and efficacy of the antibody-drug conjugate BAY 79-4620 targeting human carbonic anhydrase 9. Mol Cancer Ther. 2012 Feb;11(2):340-9.
• [32] Application of monoclonal antibody G250 recognizing carbonic anhydrase IX in renal cell carcinoma. Int J Mol Sci. 2013 May 29;14(6):11402-23.